feed,title,long_url,short_url
Benzinga,Horizon Therapeutics Begins Patient Enrolment in Phase 2 trial of Daxdilimab (HZN-7734) for Alopecia Areata,https://benzinga.com/general/biotech/22/05/27251513/horizon-therapeutics-begins-patient-enrolment-in-phase-2-trial-of-daxdilimab-hzn-7734-for-alopeci,https://bit.ly/39tnwmC
